Search Results

Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation.

• Authors : Ribchester, Richard R. (AUTHOR); Thomson, Derek (AUTHOR); Wood, Nigel I. (AUTHOR)

Subjects: HUNTINGTON disease; MUSCULAR atrophy; MYONEURAL junction

• Source: European Journal of Neuroscience. Dec2004, Vol. 20 Issue 11, p3092-3114. 23p.

Record details

MicroRNA signatures of endogenous Huntingtin CAG repeat expansion in mice.

• Authors : Langfelder, Peter; Gao, Fuying; Wang, Nan

Subjects: MICRORNA; HUNTINGTON'S chorea diagnosis; RNA sequencing

• Source: PLoS ONE; 1/11/2018, Vol. 13 Issue 1, p1-20, 20p

Record details

Possible use of a H3R antagonist for the management of nonmotor symptoms in the Q175 mouse model of Huntington's disease.

• Authors : Whittaker, Daniel S.; Wang, Huei‐Bin; Loh, Dawn H.

Subjects: ANTIHISTAMINES; HUNTINGTON'S chorea treatment; SYMPTOMS

• Source: Pharmacology Research & Perspectives; Oct2017, Vol. 5 Issue 5, pn/a-N.PAG, 17p

Record details

Cognitive training modifies disease symptoms in a mouse model of Huntington's disease.

• Authors : Yhnell, Emma¹ ; Lelos, Mariah J.¹; Dunnett, Stephen B.¹

Subjects: *ANIMAL models in research; *HUNTINGTON disease; *HUNTINGTON'S chorea treatment

• Source: Experimental Neurology. Aug2016, Vol. 282, p19-26. 8p.

Record details

Adult neural progenitor cells from Huntington's disease mouse brain exhibit increased proliferation and migration due to enhanced calcium and ROS signals.

• Authors : Xie, Wenjuan; Wang, Jiu‐Qiang; Wang, Qiao‐Chu

Subjects: PROGENITOR cells; HUNTINGTON'S chorea treatment; CELLULAR signal transduction

• Source: Cell Proliferation. Oct2015, Vol. 48 Issue 5, p517-531. 15p.

Record details

Putting the Brakes on Huntington Disease in a Mouse Experimental Model.

• Authors : Kim, Jane C.¹; Mirkin, Sergei M.¹

Subjects: *HUNTINGTON disease; *LABORATORY mice; *DNA repair

• Source: PLoS Genetics. 8/6/2015, Vol. 11 Issue 8, p1-4. 4p.

Record details

Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.

• Authors : Squitieri, Ferdinando; Di Pardo, Alba; Favellato, Mariagrazia

Subjects: HUNTINGTON'S chorea treatment; TREATMENT of neurodegeneration; NEUROPROTECTIVE agents

• Source: Journal of Cellular & Molecular Medicine; Nov2015, Vol. 19 Issue 11, p2540-2548, 9p

Record details

Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression.

• Authors : Petr, Geraldine T.; Schultheis, Laurel A.; Hussey, Kayla C.

Subjects: GLUTAMATE transporters; HUNTINGTON'S chorea diagnosis; DRUG administration

• Source: European Journal of Neuroscience. Aug2013, Vol. 38 Issue 3, p2477-2490. 14p. 1 Black and White Photograph, 7 Graphs.

Record details

The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington’s Disease Mice.

• Authors : Jia, Haiqun; Wang, Ying; Morris, Charles D.

Subjects: HUNTINGTON'S chorea treatment; HISTONE deacetylase inhibitors; EPIGENETICS

• Source: PLoS ONE; 3/31/2016, Vol. 11 Issue 3, p1-14, 14p

Record details

Therapeutic Effect of Berberine on Huntington’s Disease Transgenic Mouse Model.

• Authors : Jiang, Wenxiao; Wei, Wenjie; Gaertig, Marta A.

Subjects: HUNTINGTON'S chorea treatment; BERBERINE; DRUG efficacy

• Source: PLoS ONE; 7/30/2015, Vol. 10 Issue 7, p1-16, 16p

Record details

Compensatory mechanisms in genetic models of neurodegeneration: are the mice better than humans?

• Authors : Kreiner, Grzegorz

Subjects: RISK factors of neurodegeneration; DRUG therapy; CELL death

• Source: Frontiers in Cellular Neuroscience; Mar2015, Vol. 9, p1-6, 6p

Record details

NGF Rescues Hippocampal Cholinergic Neuronal Markers, Restores Neurogenesis, and Improves the Spatial Working Memory in a Mouse Model of Huntington's Disease.

• Authors : Zhang, Hongyu; Petit, Géraldine H.; Gaughwin, Philip M.

Subjects: HUNTINGTON'S chorea treatment; DRUG administration; LABORATORY mice

• Source: Journal of Huntington's Disease; 2013, Vol. 2 Issue 1, p69-82, 14p

Record details

Differential nuclear localization of complexes may underlie in vivo intrabody efficacy in Huntington's disease.

• Authors : Butler, D.C.; Snyder-Keller, A.; De Genst, E.

Subjects: HUNTINGTON'S chorea treatment; POLYGLUTAMINE; NEURODEGENERATION

• Source: PEDS: Protein Engineering, Design & Selection; Oct2014, Vol. 27 Issue 10, p359-363, 5p

Record details

AAV-Dominant Negative Tumor Necrosis Factor (DN-TNF) Gene Transfer to the Striatum Does Not Rescue Medium Spiny Neurons in the YAC128 Mouse Model of Huntington's Disease.

• Authors : Alto, Laura Taylor; Chen, Xi; Ruhn, Kelly A.

Subjects: TUMOR necrosis factors; GENETIC transformation; YEAST artificial chromosomes

• Source: PLoS ONE; May2014, Vol. 9 Issue 5, p1-12, 12p

Record details

Screening of Therapeutic Strategies for Huntington's Disease in YAC128 Transgenic Mice.

• Authors : Gil-Mohapel, Joana M.

Subjects: HUNTINGTON'S chorea treatment; MEDICAL screening; LABORATORY mice

• Source: CNS Neuroscience & Therapeutics; Jan2012, Vol. 18 Issue 1, p77-86, 10p

Record details

Detection of proteomic alterations at different stages in a Huntington's disease mouse model via matrix‐assisted laser desorption/ionization mass spectrometry (MALDI‐MS) imaging.

• Authors : Karayel‐Basar, Merve (AUTHOR); Uras, Irep (AUTHOR); Kiris, Irem (AUTHOR)

Subjects: MATRIX-assisted laser desorption-ionization; HUNTINGTON disease; MASS spectrometry

• Source: European Journal of Neuroscience. Aug2023, Vol. 58 Issue 4, p2985-3002. 18p. 2 Color Photographs, 1 Diagram, 3 Graphs.

Record details

In Vivo Identification of Therapeutic Constructs from Pooled Candidates in HD Model Mice.

• Authors : Crook, Zachary R.; Housman, David E.

Subjects: ANIMAL models in research; HUNTINGTON disease; LABORATORY mice

• Source: Journal of Huntington's Disease; 2013, Vol. 2 Issue 4, p437-441, 5p

Record details

Striatal Infusion of Glial Conditioned Medium Diminishes Huntingtin Pathology in R6/1 Mice.

• Authors : Perucho, Juan; Casarejos, Maria José; Gómez, Ana

Subjects: HUNTINGTON'S chorea treatment; NEUROPROTECTIVE agents; NEUROGLIA

• Source: PLoS ONE; Sep2013, Vol. 8 Issue 9, p1-10, 10p

Record details

Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.

• Authors : Jin, Jing; Albertz, Jennifer; Guo, Zhihong

Subjects: HUNTINGTON'S chorea treatment; ROSIGLITAZONE; NEUROPROTECTIVE agents

• Source: Journal of Neurochemistry; May2013, Vol. 125 Issue 3, p410-419, 10p, 5 Graphs

Record details

Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the R6/2 Mouse Model of HD.

• Authors : Rattray, Ivan; Smith, Edward; Gale, Richard

Subjects: HUNTINGTON'S chorea diagnosis; BEHAVIOR disorders; MAGNETIC resonance imaging of the brain

• Source: PLoS ONE; Apr2013, Vol. 8 Issue 4, p1-15, 15p

Record details

Intravitreal Administration of HA-1077, a ROCK Inhibitor, Improves Retinal Function in a Mouse Model of Huntington Disease.

• Authors : Li, Mei; Yasumura, Douglas; Ma, Aye Aye K.

Subjects: HUNTINGTON'S chorea treatment; NEURODEGENERATION; HUNTINGTIN protein

• Source: PLoS ONE; Feb2013, Vol. 8 Issue 2, p1-8, 8p

Record details

Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice.

• Authors : Crook, Zachary R.; Housman, David E.

Subjects: DOPAMINE receptors; HUNTINGTON'S chorea treatment; LABORATORY mice

• Source: Proceedings of the National Academy of Sciences of the United States of America; 5/8/2012, Vol. 109 Issue 19, p7487-7492, 6p

Record details

Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise.

• Authors : Renoir, Thibault; Pang, Terence YC; Zajac, Michelle S

Subjects: LABORATORY mice; HUNTINGTON'S chorea treatment; ANIMAL models of mental depression

• Source: British Journal of Pharmacology; Mar2012, Vol. 165 Issue 5, p1375-1389, 15p

Record details

Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease.

Subjects: CURCUMIN; HUNTINGTON'S chorea treatment; DIETARY supplements

• Source: Molecular Neurodegeneration; 2012, Vol. 7 Issue 1, p12-27, 16p, 1 Black and White Photograph, 5 Charts, 8 Graphs

Record details

Combined Treatment with the Mood Stabilizers Lithium and Valproate Produces Multiple Beneficial Effects in Transgenic Mouse Models of Huntington's Disease.

• Authors : Chiu, Chi-Tso; Liu, Guangping; Leeds, Peter

Subjects: THERAPEUTIC use of lithium; VALPROIC acid; GLYCOGEN synthase kinase-3

• Source: Neuropsychopharmacology; Nov2011, Vol. 36 Issue 12, p2406-2421, 16p, 1 Chart, 9 Graphs

Record details